Global accessibility of therapeutics for diabetes mellitus

Diabetes mellitus is a global health issue, yet huge regional disparities exist in its care, including in access to basic necessities such as insulin. In this Viewpoint, six experts from different regions discuss differences in access to insulin and other diabetes mellitus therapies as well as the k...

Descripción completa

Detalles Bibliográficos
Autores principales: Fralick, Michael, Jenkins, Alicia J., Khunti, Kamlesh, Mbanya, Jean Claude, Mohan, Viswanathan, Schmidt, Maria Inês
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762447/
https://www.ncbi.nlm.nih.gov/pubmed/35039662
http://dx.doi.org/10.1038/s41574-021-00621-y
_version_ 1784633765265408000
author Fralick, Michael
Jenkins, Alicia J.
Khunti, Kamlesh
Mbanya, Jean Claude
Mohan, Viswanathan
Schmidt, Maria Inês
author_facet Fralick, Michael
Jenkins, Alicia J.
Khunti, Kamlesh
Mbanya, Jean Claude
Mohan, Viswanathan
Schmidt, Maria Inês
author_sort Fralick, Michael
collection PubMed
description Diabetes mellitus is a global health issue, yet huge regional disparities exist in its care, including in access to basic necessities such as insulin. In this Viewpoint, six experts from different regions discuss differences in access to insulin and other diabetes mellitus therapies as well as the key barriers in diabetes mellitus care accessibility and potential solutions.
format Online
Article
Text
id pubmed-8762447
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87624472022-01-18 Global accessibility of therapeutics for diabetes mellitus Fralick, Michael Jenkins, Alicia J. Khunti, Kamlesh Mbanya, Jean Claude Mohan, Viswanathan Schmidt, Maria Inês Nat Rev Endocrinol Viewpoint Diabetes mellitus is a global health issue, yet huge regional disparities exist in its care, including in access to basic necessities such as insulin. In this Viewpoint, six experts from different regions discuss differences in access to insulin and other diabetes mellitus therapies as well as the key barriers in diabetes mellitus care accessibility and potential solutions. Nature Publishing Group UK 2022-01-17 2022 /pmc/articles/PMC8762447/ /pubmed/35039662 http://dx.doi.org/10.1038/s41574-021-00621-y Text en © Springer Nature Limited 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Viewpoint
Fralick, Michael
Jenkins, Alicia J.
Khunti, Kamlesh
Mbanya, Jean Claude
Mohan, Viswanathan
Schmidt, Maria Inês
Global accessibility of therapeutics for diabetes mellitus
title Global accessibility of therapeutics for diabetes mellitus
title_full Global accessibility of therapeutics for diabetes mellitus
title_fullStr Global accessibility of therapeutics for diabetes mellitus
title_full_unstemmed Global accessibility of therapeutics for diabetes mellitus
title_short Global accessibility of therapeutics for diabetes mellitus
title_sort global accessibility of therapeutics for diabetes mellitus
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762447/
https://www.ncbi.nlm.nih.gov/pubmed/35039662
http://dx.doi.org/10.1038/s41574-021-00621-y
work_keys_str_mv AT fralickmichael globalaccessibilityoftherapeuticsfordiabetesmellitus
AT jenkinsaliciaj globalaccessibilityoftherapeuticsfordiabetesmellitus
AT khuntikamlesh globalaccessibilityoftherapeuticsfordiabetesmellitus
AT mbanyajeanclaude globalaccessibilityoftherapeuticsfordiabetesmellitus
AT mohanviswanathan globalaccessibilityoftherapeuticsfordiabetesmellitus
AT schmidtmariaines globalaccessibilityoftherapeuticsfordiabetesmellitus

Ejemplares similares